AZA Combined With RCHOP in P53-mutated DLBCL.

To evaluate the efficacy and adverse effects of Azacitidine in combination with R-CHOP (ARCHOP) for the treatment of TP53-mutated previously untreated Diffuse large B-cell lymphoma

Trial Details

NCT ID
NCT06158399
Phase
PHASE2
Sponsor
The First Affiliated Hospital of Xiamen University
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Azacitidine in combination with R-CHOP
Locations (sample)
  • Xiamen, Fujian, China|24.47979,118.08187

Key Eligibility Criteria

  • (1)18-70 years old; 2) New-onset TP53 mutant DLBCL; 3) ECOG 0-2; 4) LVEF \>45%; 5) HBV-positive serology (occult carriers: anti-HBeAg +, HbsAg-, an…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →